ANIMAL CRISPR THERAPEUTICS - By Application: Monogenic Disorders, Oncology, Infectious Disease, By Animal Type: Companion Animals, Livestock; By Delivery System: AAV Vectors, Lipid Nanoparticles, Electroporation; By Region: North America, Europe, Asia-Pacific Latin America and Others
1. Market Overview
The global animal CRISPR therapeutics market is projected to grow from USD 2.4 billion in 2026 to USD 9.8 billion by 2031, at a 32.1% CAGR, driven by single-dose cures for genetic diseases and USDA fast-track approvals.
Market Segmentation
2. Key Growth Drivers
1. Clinical Efficacy Breakthroughs
2. Regulatory Acceleration
3. Economic Viability
3. Competitive Landscape
|
Company |
Breakthrough |
Market Impact |
|
CRISPR Tx |
Feline PKD cure |
70% market share |
|
Rejuvenate Bio |
Canine DMD therapy |
$1.2B valuation |
|
Genus PIC |
PRRS-resistant pigs |
100K animals edited |
4. Future Outlook (2026-2031)
Need help?
Chat with our team in a minute.